nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-231-11-170-177nogr-2980Research ArticleОБЗОРREVIEWЭффективность аутопробиотиков для восстановления микробиоты и повышения качества жизни у пациентов с колоректальным раком, получающих химиотерапиюThe effectiveness of autoprobiotics to restore the microbiota and improve the quality of life in patients with colorectal cancer receiving chemotherapyhttps://orcid.org/0000-0002-2569-6660ЕрмоленкоЕ. И.ErmolenkoE. I.noemail@neicon.ruhttps://orcid.org/0000-0001-7429-0336БарышниковаН. В.BaryshnikovaN. V.baryshnikova_nv@mail.ruhttps://orcid.org/0000-0001-6990-3193КовалисС. А.KovalisS. A.noemail@neicon.ruНовиковаН. С.NovikovaN. S.noemail@neicon.ruhttps://orcid.org/0000-0003-2152-1019ОрловаВ. В.OrlovaV. V.noemail@neicon.ruhttps://orcid.org/0000-0002-7925-7743ИльинаА. С.IlyinaA. S.noemail@neicon.ruКащенкоВ. А.KashchenkoV. A.noemail@neicon.ruhttps://orcid.org/0000-0003-2312-5589СуворовА. Н.SuvorovA. N.noemail@neicon.ruФедеральное государственное бюджетное научное учреждение «Институт Экспериментальной Медицины»РоссияInstitute of Experimental MedicineRussian FederationФедеральное государственное бюджетное научное учреждение «Институт Экспериментальной Медицины»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияInstitute of Experimental Medicine; St. Petersburg State Pediatric Medical University; Pavlov First St. Petersburg State Medical UniversityRussian FederationСеверо-Западный окружной научно-клинический центр им. Л.Г. СоколоваРоссияNorth-Western district scientific and clinical center named after L.G. SokolovRussian FederationФедеральное государственное бюджетное научное учреждение «Институт Экспериментальной Медицины»; Северо-Западный окружной научно-клинический центр им. Л.Г. СоколоваРоссияInstitute of Experimental Medicine; North-Western district scientific and clinical center named after L.G. SokolovRussian FederationСеверо-Западный окружной научно-клинический центр им. Л.Г. Соколова; Клиника высоких технологий «Белоостров», тер. «Клиника «Белоостров»РоссияNorth-Western district scientific and clinical center named after L.G. Sokolov; Beloostrov Clinic of High TechnologiesRussian Federation202417112024011170177Copyright © Ермоленко Е.И., Барышникова Н.В., Ковалис С.А., Новикова Н.С., Орлова В.В., Ильина А.С., Кащенко В.А., Суворов А.Н., 20242024Ермоленко Е.И., Барышникова Н.В., Ковалис С.А., Новикова Н.С., Орлова В.В., Ильина А.С., Кащенко В.А., Суворов А.Н.Ermolenko E.I., Baryshnikova N.V., Kovalis S.A., Novikova N.S., Orlova V.V., Ilyina A.S., Kashchenko V.A., Suvorov A.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2980

В статье представлены данные, подтверждающие эффективность микробной терапии колоректального рака (КРР), и необходимости использования пробиотиков и аутопробиотиков для коррекции нарушений, связанных с использованием цитостатиков, вызывающих побочные эффекты и дополнительные нарушения кишечного миробиоценоза. Проанализированы литературные данные, свидетельствующие о специфическом действии отдельных химиопрепаратов и пробиотиков. На клиническом примере продемонстрирована эффективность использования индигенных полезных бактерий (аутопробиотических энтерококков), выделенных из организма пациентов с КРР и введенных в период использования 5-фторцитозина, цисплатина и лейковорина. Применение пробиотиков и аутопробиотиков при терапии КРР является перспективным направлением, требующим дополнительных клинических исследований и контроля изменений кишечного микробиоценоза для снижения рисков развития послеоперационных осложнений, повышения эффективности.

The article presents data on the effectiveness of microbial therapy for colorectal cancer (CRC) and the need to use probiotics and autoprobiotics to correct disorders associated with the use of cytostatics that cause side effects and additional disorders of intestinal myrobiocenosis. The literature data indicating the specific effect of individual chemotherapy drugs and probiotics are analyzed. The clinical example demonstrates the effectiveness of the use of indigenous beneficial bacteria (autoprobiotic enterococci) isolated from the body of patients with CRC and introduced during the use of 5-fluorocytosine, cisplatin and leucovorin. The use of probiotics and autoprobiotics in the treatment of CRC is a promising area that requires additional clinical studies and monitoring of changes in intestinal microbiocenosis to reduce the risks of postoperative complications, increase the effectiveness and tolerability of the basic chemotherapeutic regimen, as well as improve the quality of life.

микробиомаутопробиотикипробиотикиEnterococcus sppдисбиоз кишечникаmicrobiomeautoprobioticsprobioticsEnterococcus sppgut dysbiosisReferencesWu N., Yang X., Zhang R. et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013 Aug;66(2):462-70. doi: 10.1007/s00248-013-0245-9.Wu N., Yang X., Zhang R. et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013 Aug;66(2):462-70. doi: 10.1007/s00248-013-0245-9.Tarashi S., Siadat SD., Ahmadi Badi S. et al. Gut Bacteria and their Metabolites: Which One Is the Defendant for Colorectal Cancer? Microorganisms. 2019 Nov 13;7(11):561. doi: 10.3390/microorganisms7110561.Tarashi S., Siadat SD., Ahmadi Badi S. et al. Gut Bacteria and their Metabolites: Which One Is the Defendant for Colorectal Cancer? Microorganisms. 2019 Nov 13;7(11):561. doi: 10.3390/microorganisms7110561.Johnson C.M., Wei C., Ensor J.E. et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013 Jun;24(6):1207-22. doi: 10.1007/s10552-013-0201-5.Johnson C.M., Wei C., Ensor J.E. et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013 Jun;24(6):1207-22. doi: 10.1007/s10552-013-0201-5.Yu J., Feng Q., Wong S.H. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017 Jan;66(1):70-78. doi: 10.1136/gutjnl-2015-309800.Yu J., Feng Q., Wong S.H. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017 Jan;66(1):70-78. doi: 10.1136/gutjnl-2015-309800.Cougnoux A., Delmas J., Gibold L. et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut. 2016 Feb;65(2):278-85. doi: 10.1136/gutjnl-2014-307241.Cougnoux A., Delmas J., Gibold L. et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut. 2016 Feb;65(2):278-85. doi: 10.1136/gutjnl-2014-307241.Sánchez-Alcoholado L., Ramos-Molina B., Otero A. et al. The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Respons. Cancers (Basel). 2020 May 29;12(6):1406. doi: 10.3390/cancers12061406.Sánchez-Alcoholado L., Ramos-Molina B., Otero A. et al. The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Respons. Cancers (Basel). 2020 May 29;12(6):1406. doi: 10.3390/cancers12061406.Karamzin A.M., Ropot A.V., Boshian R.E. Relationship of the mucin-degrading bacterium Akkermansia muciniphila with colorectal cancer. Experimental and Clinical Gastroenterology. 2020;178(6): 158-165. (In Russ.) doi: 10.31146/1682-8658-ecg-178-6-158-165.Karamzin A.M., Ropot A.V., Boshian R.E. Relationship of the mucin-degrading bacterium Akkermansia muciniphila with colorectal cancer. Experimental and Clinical Gastroenterology. 2020;178(6): 158-165. (In Russ.) doi: 10.31146/1682-8658-ecg-178-6-158-165.Tsoi H., Chu ESH., Zhang X. et al. Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology. 2017 May;152(6):1419-1433.e5. doi: 10.1053/j.gastro.2017.01.009.Tsoi H., Chu ESH., Zhang X. et al. Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology. 2017 May;152(6):1419-1433.e5. doi: 10.1053/j.gastro.2017.01.009.Dulal S., Keku T.O. Gut microbiome and colorectal adenomas. Cancer J. 2014 May-Jun;20(3):225-31. doi: 10.1097/PPO.0000000000000050.Dulal S., Keku T.O. Gut microbiome and colorectal adenomas. Cancer J. 2014 May-Jun;20(3):225-31. doi: 10.1097/PPO.0000000000000050.Wu X., Wu Y., He L., Wu L., Wang X., Liu Z. Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer. J Cancer. 2018 Jun 15;9(14):2510-2517. doi: 10.7150/jca.25324.Wu X., Wu Y., He L., Wu L., Wang X., Liu Z. Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer. J Cancer. 2018 Jun 15;9(14):2510-2517. doi: 10.7150/jca.25324.Kochkina S.O., Gordeev S.S., Mamedli Z.Z. Role of human microbiota in the development of colorectal cancer. Pelvic Surgery and Oncology. 2019; 9(3):11-17. doi: 10.17650/2686-9594-2019-9-3-11-17.Kochkina S.O., Gordeev S.S., Mamedli Z.Z. Role of human microbiota in the development of colorectal cancer. Pelvic Surgery and Oncology. 2019; 9(3):11-17. doi: 10.17650/2686-9594-2019-9-3-11-17.Alasiri G.A. Effect of gut microbiota on colorectal cancer progression and treatment. Saudi Med J. 2022 Dec;43(12):1289-1299. doi: 10.15537/smj.2022. 43.12.20220367.Alasiri G.A. Effect of gut microbiota on colorectal cancer progression and treatment. Saudi Med J. 2022 Dec;43(12):1289-1299. doi: 10.15537/smj.2022. 43.12.20220367.Zakharenko A.A., Suvorov A.N., Shlyk I.V., Ten O.A., Dzhamilov S.R., Natkha A.S., Trushin A.A., Belyaev M.A. Disorders of a microbiocenosis of intestines at patients with a colorectal cancer and ways of their correction (review). Coloproctology. 2016; 2 (56): 48-56. doi: 10.33878/2073-7556-2016-0-2-48-56.@@ Захаренко А.А., Суворов А.Н., Шлык И.В., Тен О.А., Жамилов Ш.Р., Натха А.С., Беляев М.А. Нарушения микробиоценоза кишечника у больных колоректальным раком и способы их коррекции (обзор литературы). Колопроктология 2016; 2: 48-56. (in Russ.) doi: 10.33878/2073-7556-2016-0-2-48-56.Zakharenko A.A., Suvorov A.N., Shlyk I.V., Ten O.A., Dzhamilov S.R., Natkha A.S., Trushin A.A., Belyaev M.A. Disorders of a microbiocenosis of intestines at patients with a colorectal cancer and ways of their correction (review). Coloproctology. 2016; 2 (56): 48-56. doi: 10.33878/2073-7556-2016-0-2-48-56.@@ Захаренко А.А., Суворов А.Н., Шлык И.В., Тен О.А., Жамилов Ш.Р., Натха А.С., Беляев М.А. Нарушения микробиоценоза кишечника у больных колоректальным раком и способы их коррекции (обзор литературы). Колопроктология 2016; 2: 48-56. (in Russ.) doi: 10.33878/2073-7556-2016-0-2-48-56.Johnson C.M., Wei C., Ensor J.E., Smolenski D.J., Amos C.I., Levin B. et al. Meta-analyses of colorectal cancer risk factors. Cancer causes & control. 2013 Mar; 4: 1207-1222. doi: 10.1007/s10552-013-0201-5.Johnson C.M., Wei C., Ensor J.E., Smolenski D.J., Amos C.I., Levin B. et al. Meta-analyses of colorectal cancer risk factors. Cancer causes & control. 2013 Mar; 4: 1207-1222. doi: 10.1007/s10552-013-0201-5.Kharchenko E.P., Soloviev I.A. microbiota, immune system and colorectal cancer. Pelvic Surgery and Oncology. 2017; 4: 11-19. (In Russ.) doi: 10.17650/2220-3478-2017-7-4-11-19.@@ Харченко Е.П., Соловьев И.А. Микробиота, иммунная система и колоректальный рак. Тазовая хирургия и онкология. 2017; 4: 11-19. doi: 10.17650/2220-3478-2017-7-4-11-19.Kharchenko E.P., Soloviev I.A. microbiota, immune system and colorectal cancer. Pelvic Surgery and Oncology. 2017; 4: 11-19. (In Russ.) doi: 10.17650/2220-3478-2017-7-4-11-19.@@ Харченко Е.П., Соловьев И.А. Микробиота, иммунная система и колоректальный рак. Тазовая хирургия и онкология. 2017; 4: 11-19. doi: 10.17650/2220-3478-2017-7-4-11-19.Cammarota G., Ianiro G. Gut Microbiota and Cancer Patients: A Broad-Ranging Relationship. Mayo Clin Proc. 2017 Nov;92(11):1605-1607. doi: 10.1016/j.mayocp.2017.09.009.Cammarota G., Ianiro G. Gut Microbiota and Cancer Patients: A Broad-Ranging Relationship. Mayo Clin Proc. 2017 Nov;92(11):1605-1607. doi: 10.1016/j.mayocp.2017.09.009.Li H. L. et al. Alteration of gut microbiota and inflammatory cytokine/chemokine profiles in 5-fluorouracil induced intestinal mucositis. Frontiers in cellular and infection microbiology. 2017;(7):455.Li H. L. et al. Alteration of gut microbiota and inflammatory cytokine/chemokine profiles in 5-fluorouracil induced intestinal mucositis. Frontiers in cellular and infection microbiology. 2017;(7):455.Yeung C.Y. et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PloS one. 2015;10(9): e0138746.Yeung C.Y. et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PloS one. 2015;10(9): e0138746.Yin B., Wang X., Yuan F., Li Y., Lu P. Research progress on the effect of gut and tumor microbiota on antitumor efficacy and adverse effects of chemotherapy drugs. Front. Microbiol. 2022;13:899111. doi: 10.3389/fmicb.2022.899111.Yin B., Wang X., Yuan F., Li Y., Lu P. Research progress on the effect of gut and tumor microbiota on antitumor efficacy and adverse effects of chemotherapy drugs. Front. Microbiol. 2022;13:899111. doi: 10.3389/fmicb.2022.899111.Raymond E., Chaney SG., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. doi: 10.1023/a: 1008213732429.Raymond E., Chaney SG., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. doi: 10.1023/a: 1008213732429.Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 2007 Sep;96(9):2181-96. doi: 10.1002/jps.20874.Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 2007 Sep;96(9):2181-96. doi: 10.1002/jps.20874.Cogdill A.P., Gaudreau P.O., Arora R., Gopalakrishnan V., Wargo J.A. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol. 2018 Nov;39(11):900-920. doi: 10.1016/j.it.2018.09.007.Cogdill A.P., Gaudreau P.O., Arora R., Gopalakrishnan V., Wargo J.A. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol. 2018 Nov;39(11):900-920. doi: 10.1016/j.it.2018.09.007.von Frieling J., Fink C., Hamm J. et al. Microbial Effects on Epithelial Proliferation, Carcinogenesis, and Cancer Therapy. Front Microbiol. 2018 Sep 20;9:2020. doi: 10.3389/fmicb.2018.02020.von Frieling J., Fink C., Hamm J. et al. Microbial Effects on Epithelial Proliferation, Carcinogenesis, and Cancer Therapy. Front Microbiol. 2018 Sep 20;9:2020. doi: 10.3389/fmicb.2018.02020.Iida N., Dzutsev A., Stewart C.A. et al.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013 Nov 22;342(6161):967-70. doi: 10.1126/science.1240527.Iida N., Dzutsev A., Stewart C.A. et al.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013 Nov 22;342(6161):967-70. doi: 10.1126/science.1240527.Wilkinson E.M., Ilhan Z.E., Herbst-Kralovetz M.M. Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics. Maturitas. 2018 Jun;112:53-63. doi: 10.1016/j.maturitas.2018.03.012.Wilkinson E.M., Ilhan Z.E., Herbst-Kralovetz M.M. Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics. Maturitas. 2018 Jun;112:53-63. doi: 10.1016/j.maturitas.2018.03.012.Lin C., Cai X., Zhang J. et al. Role of Gut Microbiota in the Development and Treatment of Colorectal Cancer. Digestion. 2019;100(1):72-78. doi: 10.1159/000494052.Lin C., Cai X., Zhang J. et al. Role of Gut Microbiota in the Development and Treatment of Colorectal Cancer. Digestion. 2019;100(1):72-78. doi: 10.1159/000494052.Perez-Chanona E., Trinchieri G. The role of microbiota in cancer therapy. Curr Opin Immunol. 2016 Apr;39:75-81. doi: 10.1016/j.coi.2016.01.003.Perez-Chanona E., Trinchieri G. The role of microbiota in cancer therapy. Curr Opin Immunol. 2016 Apr;39:75-81. doi: 10.1016/j.coi.2016.01.003.Joyce K., Saxena S., Williams A. et al. Antimicrobial spectrum of the antitumor agent, cisplatin. J Antibiot (Tokyo). 2010 Aug;63(8):530-2. doi: 10.1038/ja.2010.64.Joyce K., Saxena S., Williams A. et al. Antimicrobial spectrum of the antitumor agent, cisplatin. J Antibiot (Tokyo). 2010 Aug;63(8):530-2. doi: 10.1038/ja.2010.64.Pflug N., Kluth S., Vehreschild J.J. et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology. 2016 Apr 22;5(6): e1150399. doi: 10.1080/2162402X.2016.1150399.Pflug N., Kluth S., Vehreschild J.J. et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology. 2016 Apr 22;5(6): e1150399. doi: 10.1080/2162402X.2016.1150399.Pereira V.B., Melo A.T., Assis-Júnior E.M. et al. A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. Cancer Chemother Pharmacol. 2016 Feb;77(2):323-32. doi: 10.1007/s00280-015-2938-x.Pereira V.B., Melo A.T., Assis-Júnior E.M. et al. A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. Cancer Chemother Pharmacol. 2016 Feb;77(2):323-32. doi: 10.1007/s00280-015-2938-x.Nijhuis A., Thompson H., Adam J. et al. Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Hum Mol Genet. 2017 Apr 15;26(8):1552-1564. doi: 10.1093/hmg/ddx059.Nijhuis A., Thompson H., Adam J. et al. Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Hum Mol Genet. 2017 Apr 15;26(8):1552-1564. doi: 10.1093/hmg/ddx059.Yuan L., Zhang S., Li H. et al. The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. Biomed Pharmacother. 2018 Dec;108:184-193. doi: 10.1016/j.biopha.2018.08.165.Yuan L., Zhang S., Li H. et al. The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. Biomed Pharmacother. 2018 Dec;108:184-193. doi: 10.1016/j.biopha.2018.08.165.Daillère R., Vétizou M., Waldschmitt N. et al. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009.Daillère R., Vétizou M., Waldschmitt N. et al. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009.Viaud S., Saccheri F., Mignot G. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.Viaud S., Saccheri F., Mignot G. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.Quaresma M. et al. Probiotic mixture containing Lactobacillus spp. and Bifidobacterium spp. attenuates 5-fluorouracil-induced intestinal mucositis in mice. Nutrition and Cancer. 2020;72(8):1355-1365.Quaresma M. et al. Probiotic mixture containing Lactobacillus spp. and Bifidobacterium spp. attenuates 5-fluorouracil-induced intestinal mucositis in mice. Nutrition and Cancer. 2020;72(8):1355-1365.Yeung C.Y. et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PloS one. 2015;10(9): e0138746.Yeung C.Y. et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PloS one. 2015;10(9): e0138746.Tooley K.L. et al. Oral ingestion of Streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer biology & therapy. 2006;5(6):593-600.Tooley K.L. et al. Oral ingestion of Streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer biology & therapy. 2006;5(6):593-600.Österlund P. et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. British journal of cancer. 2007;97(8):1028-1034.Österlund P. et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. British journal of cancer. 2007;97(8):1028-1034.Floch M.H. The Role of Prebiotics and Probiotics in Gastrointestinal Disease. Gastroenterol Clin North Am. 2018 Mar;47(1):179-191. doi: 10.1016/j.gtc.2017.09.011.Floch M.H. The Role of Prebiotics and Probiotics in Gastrointestinal Disease. Gastroenterol Clin North Am. 2018 Mar;47(1):179-191. doi: 10.1016/j.gtc.2017.09.011.Zaharuddin L., Mokhtar N.M., Muhammad Nawawi K.N., Raja Ali R.A. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019 Jul 24;19(1):131. doi: 10.1186/s12876-019-1047-4.Zaharuddin L., Mokhtar N.M., Muhammad Nawawi K.N., Raja Ali R.A. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019 Jul 24;19(1):131. doi: 10.1186/s12876-019-1047-4.Consoli M.L., da Silva R.S., Nicoli J.R. et al. Randomized Clinical Trial: Impact of Oral Administration of Saccharomyces boulardii on Gene Expression of Intestinal Cytokines in Patients Undergoing Colon Resection. JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1114-1121. doi: 10.1177/0148607115584387.Consoli M.L., da Silva R.S., Nicoli J.R. et al. Randomized Clinical Trial: Impact of Oral Administration of Saccharomyces boulardii on Gene Expression of Intestinal Cytokines in Patients Undergoing Colon Resection. JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1114-1121. doi: 10.1177/0148607115584387.Krebs B. Prebiotic and Synbiotic Treatment before Colorectal Surgery - Randomised Double Blind Trial. Coll Antropol. 2016 Apr;40(1):35-40. PMID: 2730123.Krebs B. Prebiotic and Synbiotic Treatment before Colorectal Surgery - Randomised Double Blind Trial. Coll Antropol. 2016 Apr;40(1):35-40. PMID: 2730123.Kim C.E., Yoon L.S., Michels K.B., Tranfield W., Jacobs J.P., May F.P. The Impact of Prebiotic, Probiotic, and Synbiotic Supplements and Yogurt Consumption on the Risk of Colorectal Neoplasia among Adults: A Systematic Review. Nutrients. 2022 Nov 21;14(22):4937. doi: 10.3390/nu14224937.Kim C.E., Yoon L.S., Michels K.B., Tranfield W., Jacobs J.P., May F.P. The Impact of Prebiotic, Probiotic, and Synbiotic Supplements and Yogurt Consumption on the Risk of Colorectal Neoplasia among Adults: A Systematic Review. Nutrients. 2022 Nov 21;14(22):4937. doi: 10.3390/nu14224937.Khakimova G.G., Tryakin A.A., Zabotina T.N., Tsukanov A.S., Aliev V.A., Gutorov S.L. The Role of the Intestinal Microbiome in the Immunotherapy of Colon Cancer. Malignant tumours. 2019;9(2):5-11. (In Russ.) doi: 10.18027/2224-5057-2019-9-2-5-11.@@ Хакимова Г.Г., Трякин А.А., Заботина Т.Н., Цуканов А.С., Алиев В.А. Роль кишечной микробиоты при иммунотерапии рака толстой кишки. Злокачественные опухоли 2019;9(2):5-11. doi: 10.18027/2224-5057-2019-9-2-5-11.Khakimova G.G., Tryakin A.A., Zabotina T.N., Tsukanov A.S., Aliev V.A., Gutorov S.L. The Role of the Intestinal Microbiome in the Immunotherapy of Colon Cancer. Malignant tumours. 2019;9(2):5-11. (In Russ.) doi: 10.18027/2224-5057-2019-9-2-5-11.@@ Хакимова Г.Г., Трякин А.А., Заботина Т.Н., Цуканов А.С., Алиев В.А. Роль кишечной микробиоты при иммунотерапии рака толстой кишки. Злокачественные опухоли 2019;9(2):5-11. doi: 10.18027/2224-5057-2019-9-2-5-11.Pitsillides L., Pellino G., Tekkis P., Kontovounisios C. The Effect of Perioperative Administration of Probiotics on Colo-rectal Cancer Surgery Outcomes. Nutrients. 2021 Apr 25;13(5):1451. doi: 10.3390/nu13051451.Pitsillides L., Pellino G., Tekkis P., Kontovounisios C. The Effect of Perioperative Administration of Probiotics on Colo-rectal Cancer Surgery Outcomes. Nutrients. 2021 Apr 25;13(5):1451. doi: 10.3390/nu13051451.Finlay B.B., Goldszmid R., Honda K., Trinchieri G., Wargo J., Zitvogel L. Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol. 2020 Sep;20(9):522-528. doi: 10.1038/s41577-020-0374-6.Finlay B.B., Goldszmid R., Honda K., Trinchieri G., Wargo J., Zitvogel L. Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol. 2020 Sep;20(9):522-528. doi: 10.1038/s41577-020-0374-6.Costa R.L., Moreira J., Lorenzo A., Lamas C.C. Infectious complications following probiotic ingestion: a potentially underestimated problem? A systematic review of reports and case series. BMC Complement Altern Med. 2018 Dec 12;18(1):329. doi: 10.1186/s12906-018-2394-3.Costa R.L., Moreira J., Lorenzo A., Lamas C.C. Infectious complications following probiotic ingestion: a potentially underestimated problem? A systematic review of reports and case series. BMC Complement Altern Med. 2018 Dec 12;18(1):329. doi: 10.1186/s12906-018-2394-3.Suvorov A., Karaseva A., Kotyleva M. et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front. Microbiol. 2018; 9:1869. doi: 10.3389/fmicb.2018.01869.Suvorov A., Karaseva A., Kotyleva M. et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front. Microbiol. 2018; 9:1869. doi: 10.3389/fmicb.2018.01869.Gromova L.V., Ermolenko E.I., Sepp A.L. et al. Gut Digestive Function and Microbiome after Correction of Experimental Dysbiosis in Rats by Indigenous Bifidobacteria. Microorganisms. 2021;9(3):522.Gromova L.V., Ermolenko E.I., Sepp A.L. et al. Gut Digestive Function and Microbiome after Correction of Experimental Dysbiosis in Rats by Indigenous Bifidobacteria. Microorganisms. 2021;9(3):522.Ermolenko E.I., Erofeev N.P., Zakharova L.B., Pariyskaya E.N., Kotyleva M.P., Suvorov A.N., Feature of the composition of the microbiota and intestinal motility after correction of experimental dysbiosis with probiotics and autoprobiotic enterococci. Experimental and clinical gastroenterology. 2017;7(143):89-96. (in Russ.)@@ Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б., Парийская Е.Н., Котылева М.П., Суворов А.Н. Особенности состава микробиоты и моторики кишечника после коррекции экспериментального дисбиоза пробиотическими и аутопробиотическими энтерококками. Экспериментальная и клиническая гастроэнтерология. 2017;7 (143):89-96.Ermolenko E.I., Erofeev N.P., Zakharova L.B., Pariyskaya E.N., Kotyleva M.P., Suvorov A.N., Feature of the composition of the microbiota and intestinal motility after correction of experimental dysbiosis with probiotics and autoprobiotic enterococci. Experimental and clinical gastroenterology. 2017;7(143):89-96. (in Russ.)@@ Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б., Парийская Е.Н., Котылева М.П., Суворов А.Н. Особенности состава микробиоты и моторики кишечника после коррекции экспериментального дисбиоза пробиотическими и аутопробиотическими энтерококками. Экспериментальная и клиническая гастроэнтерология. 2017;7 (143):89-96.Alferova L.S., Ermolenko E.I., Chernikova A.T., Novikova N.S., Anopova A.D. Vasyukova E.A., et al. Autoprobiotic enterococci as a component of complex therapy for metabolic syndrome.Russian Journal of Personalized Medicine. 2023;2(6):98-114. (in Russ.) doi: 10.18705/2782-3806-2022-2-6-98-114.@@ Алфёрова Л.С., Ермоленко Е.И., Черникова А.Т., Новикова Н.С., Анопова А.Д., Васюкова Е.А., и др. Аутопробиотические энтерококки как компонент комплексной терапии метаболического синдрома. Российский журнал персонализированной медицины. 2023;2(6):98-114. doi: 10.18705/2782-3806-2022-2-6-98-114.Alferova L.S., Ermolenko E.I., Chernikova A.T., Novikova N.S., Anopova A.D. Vasyukova E.A., et al. Autoprobiotic enterococci as a component of complex therapy for metabolic syndrome.Russian Journal of Personalized Medicine. 2023;2(6):98-114. (in Russ.) doi: 10.18705/2782-3806-2022-2-6-98-114.@@ Алфёрова Л.С., Ермоленко Е.И., Черникова А.Т., Новикова Н.С., Анопова А.Д., Васюкова Е.А., и др. Аутопробиотические энтерококки как компонент комплексной терапии метаболического синдрома. Российский журнал персонализированной медицины. 2023;2(6):98-114. doi: 10.18705/2782-3806-2022-2-6-98-114.Artemyev I.A., Ermolenko E.I., Kotyleva M.P. et al. The use of autoprobiotics in complex therapy of axial spondiloarthritis.Russian journal of Personalized Medicine. 2023;3 (1):80-97. (in Russ.)@@ Артемьев И.А., Ермоленко Е.И., Котылева М.П. и др. Использование аутопробиотиков при комплексной терапии аксиального спондилоартрита. Российский журнал персонализированной медицины. 2023;3(1): 80-97.Artemyev I.A., Ermolenko E.I., Kotyleva M.P. et al. The use of autoprobiotics in complex therapy of axial spondiloarthritis.Russian journal of Personalized Medicine. 2023;3 (1):80-97. (in Russ.)@@ Артемьев И.А., Ермоленко Е.И., Котылева М.П. и др. Использование аутопробиотиков при комплексной терапии аксиального спондилоартрита. Российский журнал персонализированной медицины. 2023;3(1): 80-97.Ermolenko E.I., Milyukhina I.V., Tsapieva A.N., Alyokhina G.G., Istomina A.S. Gracheva E.V., Kotyleva M.P., Suvorov A.N. A method for reducing the severity of non-motor symptoms in patiencets suffering from Parkinsns disease. RF patent No. 2734718 dated October 22, 2020. (in Russ.)@@ Ермоленко Е.И., Милюхина И.В., Цапиева А.Н., Алехина Г.Г., Истомина А.С., Грачева E.B., Котылева М.П., Суворов А.Н. Способ уменьшения выраженности немоторных симптомов у пациентов, страдающих болезнью Паркинсона. Патент РФ № 2734718 от 22.10.2020 г.Ermolenko E.I., Milyukhina I.V., Tsapieva A.N., Alyokhina G.G., Istomina A.S. Gracheva E.V., Kotyleva M.P., Suvorov A.N. A method for reducing the severity of non-motor symptoms in patiencets suffering from Parkinsns disease. RF patent No. 2734718 dated October 22, 2020. (in Russ.)@@ Ермоленко Е.И., Милюхина И.В., Цапиева А.Н., Алехина Г.Г., Истомина А.С., Грачева E.B., Котылева М.П., Суворов А.Н. Способ уменьшения выраженности немоторных симптомов у пациентов, страдающих болезнью Паркинсона. Патент РФ № 2734718 от 22.10.2020 г.Bakulina N.V., Tikhonov S.V., Ermolenko E.I. et al. The use of probiotic and autoprobiotic Enterococcus faecium in the treatment of patients with type 2 diabetes mellitus. Bulletin of the North-Western State Medical University named ater I.I. Mechnikov. 2022;14(1):77-88. (in Russ.) doi: 10.17816/mechnikov104795.@@ Бакулина Н.В., Тихонов С.В., Ермоленко Е.И. и др. Использование пробиотических и аутопробиотических Enterococcus faecium в лечении пациентов с сахарным диабетом 2-го типа. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2022;14(1):77-88. doi: 10.17816/mechnikov104795.Bakulina N.V., Tikhonov S.V., Ermolenko E.I. et al. The use of probiotic and autoprobiotic Enterococcus faecium in the treatment of patients with type 2 diabetes mellitus. Bulletin of the North-Western State Medical University named ater I.I. Mechnikov. 2022;14(1):77-88. (in Russ.) doi: 10.17816/mechnikov104795.@@ Бакулина Н.В., Тихонов С.В., Ермоленко Е.И. и др. Использование пробиотических и аутопробиотических Enterococcus faecium в лечении пациентов с сахарным диабетом 2-го типа. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2022;14(1):77-88. doi: 10.17816/mechnikov104795.Revicki D.A., Wood M., Wiklund I., Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998 Jan;7(1):75-83. doi: 10.1023/a:1008841022998.Revicki D.A., Wood M., Wiklund I., Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998 Jan;7(1):75-83. doi: 10.1023/a:1008841022998.Ware J.E. Jr., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. PMID: 1593914.Ware J.E. Jr., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. PMID: 1593914.Baryshnikova N.V., Belousova L.N., Petrenko V.V., Pavlova E.Y. Assessment of the quality of life of gastroenterological patients. Vrach. 2013; 7: 62-65. (in Russ.)@@ Барышникова Н.В., Белоусова Л.Н., Петренко В.В., Павлова Е.Ю. Оценка качества жизни гастроэнтерологических больных. Врач. 2013; 7: 62-65.Baryshnikova N.V., Belousova L.N., Petrenko V.V., Pavlova E.Y. Assessment of the quality of life of gastroenterological patients. Vrach. 2013; 7: 62-65. (in Russ.)@@ Барышникова Н.В., Белоусова Л.Н., Петренко В.В., Павлова Е.Ю. Оценка качества жизни гастроэнтерологических больных. Врач. 2013; 7: 62-65.

The authors declare that there are no conflicts of interest present.